LY3561774 for Dyslipidemia

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Dyslipidemia+3 MoreLY3561774 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug to see if it's effective and safe for people with mixed dyslipidemia who are already taking a statin.

Eligible Conditions
  • Dyslipidemia
  • Metabolic Diseases
  • Hyperlipoproteinemia
  • Lipid Metabolism Disorders

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 12 Secondary · Reporting Duration: Up to Day 270

Baseline, Day 180
Percent Change from Baseline for Angiopoietin-like (ANGPTL3)
Percent Change from Baseline for Apolipoprotein (ApoB)
Percent Change from Baseline for Apolipoprotein B (ApoB)
Percent Change from Baseline for High Density Lipoprotein-Cholesterol (HDL-C)
Percent Change from Baseline for Low Density Lipoprotein-Cholesterol (LDL-C)
Percent Change from Baseline for Non-High Density Lipoprotein-Cholesterol (non-HDL-C)
Percent Change from Baseline for Non-High-Density Lipoprotein-Cholesterol (non-HDL-C)
Baseline, Day 270
Percent Change from Baseline for ANGPTL3
Percent Change from Baseline for ApoB
Percent Change from Baseline for HDL-C
Percent Change from Baseline for LDL-C
Triglycerides
Percent Change from Baseline for non-HDL-C
Up to Day 270
Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of LY3561774

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

5 Treatment Groups

LY3561774 Dose 1
1 of 5
LY3561774 Dose 4
1 of 5
LY3561774 Dose 2
1 of 5
LY3561774 Dose 3
1 of 5
Placebo
1 of 5

Experimental Treatment

Non-Treatment Group

175 Total Participants · 5 Treatment Groups

Primary Treatment: LY3561774 · Has Placebo Group · Phase 2

LY3561774 Dose 1
Drug
Experimental Group · 1 Intervention: LY3561774 · Intervention Types: Drug
LY3561774 Dose 4
Drug
Experimental Group · 1 Intervention: LY3561774 · Intervention Types: Drug
LY3561774 Dose 2
Drug
Experimental Group · 1 Intervention: LY3561774 · Intervention Types: Drug
LY3561774 Dose 3
Drug
Experimental Group · 1 Intervention: LY3561774 · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3561774
2020
Completed Phase 1
~80

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to day 270

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,466 Previous Clinical Trials
3,135,224 Total Patients Enrolled
4 Trials studying Dyslipidemia
1,051 Patients Enrolled for Dyslipidemia
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)Study DirectorEli Lilly and Company
1,258 Previous Clinical Trials
369,220 Total Patients Enrolled
2 Trials studying Dyslipidemia
499 Patients Enrolled for Dyslipidemia

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have fasting LDL-C ≥100 mg/dL (2.59 mmol/L) at screening.
You have a body mass index within the range of 18.5 to 40.0 kg/m², inclusive.

Who else is applying?

What state do they live in?
Pennsylvania100.0%
How old are they?
18 - 65100.0%
What site did they apply to?
Preferred Primary Care Physicians100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%